Oncotarget

Research Perspectives:

Is miR-29 an oncogene or tumor suppressor in CLL?

Yuri Pekarsky _, Carlo M. Croce

PDF  |  Order a Reprint

Oncotarget. 2010; 1:224-227. https://doi.org/10.18632/oncotarget.129

Metrics: PDF 1728 views  |   ?  


Abstract

Received: June 21, 2010, Accepted: July 7, 2010, Published: July 8, 2010

B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH VH; indolent CLL shows low ZAP-70 expression and mutated IgH VH. We recently found that miR-29 is upregulated in indolent human B-CLL, compared to aggressive B-CLL and normal CD19+ B-cells. To determine the role of miR-29 in CLL, we generated transgenic mice overexpressing miR-29 in mouse B-cells. Recently we reported that miR-29 transgenic mice develop indolent CLL phenotype. Interestingly, our previous findings suggest that miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, indicating that miR-29 might function as a tumor suppressor in CLL. Here we discuss these results and provide additional insights into function of miR-29 in CLL.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 129